Security Snapshot

InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) Institutional Ownership

CUSIP: 457637700

13F Institutional Holders and Ownership History from Q4 2024 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

20

Shares (Excl. Options)

2.7MFull value: 2,697,637 · shares · 30 Jun 2026

Price

$1.55

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Shares, no par value
Symbol
INM on Nasdaq
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
2,697,637
Latest holder snapshot 5 signals
Total 13F value
$5,181,329
Portfolio coverage rank
0%
Share change
+2,378,336
Value change
+$4,711,680
Number of holders
20
Issuer context Names, identifiers, and filing context for this profile. 2 identity fields
Shares outstanding
5,486,442
SEC-reported price per share
$1.33
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • INM - InMed Pharmaceuticals Inc. - Common Shares, no par value is tracked under CUSIP 457637700.
  • 20 institutions reported positions in Q2 2026.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 8 to 20 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $206.03KFull value: $206,034 · USD · 31 Mar 2026
    to
    $5.18MFull value: $5,181,329 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 20 institutions filings for Q2 2026.

Open SEC evidence

Security key

457637700

13F reference period

Q2 2026

13F holders

20

13D/G owners

5

CIK / CUSIP context first

Open Q2 2026 holders INM full holder history InMed Pharmaceuticals Inc. SEC filings InMed Pharmaceuticals Inc. company facts InMed Pharmaceuticals Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
5
Security
INM
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ADAR1 Capital Management, LLC 17% -29% $1,217,332 +$185,332 943,668 +18% ADAR1 Capital Management, LLC 30 Sep 2026
Vivo Opportunity Fund Holdings, L.P. 22% $459,804 718,444 Vivo Opportunity Fund Holdings, L.P. 19 May 2026
Squadron Capital Management LLC 9.8% $208,000 325,000 Squadron Master Fund LP 19 May 2026
SABBY MANAGEMENT, LLC 9.9% $333,364 280,138 SABBY MANAGEMENT, LLC 31 Dec 2025
Ikarian Capital, LLC 4.2% $221,591 137,634 Ikarian Capital, LLC 30 Jun 2026
As of 30 Jun 2026, 20 institutional investors reported holding
2.7MFull value: 2,697,637 · shares · 30 Jun 2026
shares of InMed Pharmaceuticals Inc. - Common Shares, no par value (INM). This represents 49% of the company’s total
5.49MFull value: 5,486,442 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 22 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
49%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ADAR1 Capital Management, LLC 15% 800,000 0.06% $1,240,000
Vivo Capital, LLC 15% 798,377 0.11% $1,237,484
Squadron Capital Management LLC 5.9% 325,000 0.17% $503,750
Ikarian Capital, LLC 4.5% 245,025 0.06% $379,788
Ursa Fund Management, LLC 2.3% 125,800 0.03% $194,990
MONTANOVA CAPITAL, LLC 1.8% 100,000 0% $155,000
BOOTHBAY FUND MANAGEMENT, LLC 1.4% 74,244 0% $115,078
SABBY MANAGEMENT, LLC 0.82% 44,970 -80% 0.58% $69,704
JANE STREET GROUP, LLC 0.79% 43,078 0% $66,771
Venrock Adviser, LLC 0.6% 32,685 0% $50,662
CITADEL ADVISORS LLC 0.48% 26,084 -44% 0% $40,430
SEVEN GRAND MANAGERS, LLC 0.46% 25,000 0% $38,750
Scientech Research LLC 0.28% 15,461 0.02% $23,965
Crestwood Advisors Group, LLC 0.27% 14,900 0% $23,095
TWO SIGMA SECURITIES, LLC 0.2% 10,945 -42% 0% $16,965
Stratos Wealth Partners, LTD. 0.2% 10,760 0% $16,678
Private Wealth Management Group, LLC 0.09% 5,000 0% 0% $7,750
SBI Securities Co., Ltd. 0.01% 300 0% 0% $465
Banque Cantonale Vaudoise 0% 6 0.04% $1,000,000
Federation des caisses Desjardins du Quebec 0% 2 0% 0% $4
Virtu Financial LLC 0% 0 -100% $0
UBS Group AG 0% 0 -100% $0

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
8
Headline period
Q2 2026
Rows shown
1-8 of 8
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 20,200 $27,472 $1.36 3
2026 Q2 2,697,637 $5,181,329 +$4,711,680 $1.55 20
2026 Q1 319,301 $206,034 +$49,348 $0.64 8
2025 Q4 227,043 $240,666 -$175,633 $1.06 6
2025 Q3 303,584 $665,240 +$637,052 $2.19 8
2025 Q2 8,470 $28,508 +$7,682 $3.25 6
2025 Q1 6,408 $13,264 -$185,585 $2.04 4
2024 Q4 48,870 $226,645 +$226,645 $4.87 4
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .